Tratamiento biológico en la enfermedad pulmonar obstructiva crónica

Referencias bibliográficas

• Soriano JB, Rojas-Rueda D, Alonso J et al. La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. Med Clin (Barc) 2018; 151(5): 171–190.
• Ancochea J, Miravitlles M, García-Río F et al. Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres: Cuantificación del problema, determinantes y propuestas de acción. Arch Bronconeumol 2013; 49(6): 223–229.
• Singh D, Agusti A, Anzueto A et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019; 53(5): 1900164.
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J 2019;54(2): 1900651.
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118(11): 3.546–3.556.
• Tripple JW, McCracken JL, Calhoun WJ. Biologic Therapy in Chronic Obstructive Pulmonary Disease. Immunol. Allergy Clin. North Am. 2017; 37(2): 345–355.
• Baloira A. Fundamentos de la terapia monoclonal en EPOC. Inflamación en EPOC. Monogr Arch Bronconeumol 2017; 4: 00146.
• Yousuf A, Brightling CE. Biologic Drugs: A New Target Therapy in COPD? COPD J. Chronic Obstr. Pulm. Dis. 2018; 15(2): 99–107.
• Rogliani P, Calzetta L, Ora J et al. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015;31(February):15–27.
• Gernez Y, Tirouvanziam R, Chanez P. Neutrophils in chronic inflammatory airway diseases: Can we target them and how? Eur Respir J 2010; 35(3): 467–469.
• Rennard SI, Dale DC, Donohue JF et al. CXCR2 antagonist MK-7123 a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 191(9): 1.001–1.011.
• Singh D, Kolsum U, Brightling CE et al. Eosinophilic inflammation in COPD: Prevalence and clinical characteristics. Eur Respir J 2014; 44(6): 1.697–1.700.
• Nixon J, Newbold P, Mustelin T et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol. Ther. 2017; 169: 57–77.
• Cherry WB, Yoon J, Bartemes et al. A novel IL-1 family cytokine, IL-33, potently activates human eosinophlls. J Allergy Clin Immunol 2008; 121(6): 1.484–90.
• Martinez-Gonzalez I, Steer CA, Takei F. Lung ILC2s link innate and adaptive responses in allergic inflammation. Trends Immunol 2015; 36(3): 189–195.
• Matera MG, Calzetta L, Cazzola M. TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath water. Pulm Pharmacol Ther 2010; 23(2): 121–128.
• Malaviya R, Laskin JD, Laskin DL. AntiTNFα therapy in inflammatory lung diseases. Pharmacol Ther 2017; 180: 90–98.
• Aaron SD, Vandemheen KL, Maltais F et al. TNFα antagonists for acute exacerbations of COPD: A randomised double-blind controlled trial. Thorax 2013; 68(2): 142–148.
• Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(9): 926–934.
• Kirsten AM, Förster K, Radeczky E et al. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther 2015; 31: 36–41.
• Caramori G, Casolari P, Barczyk A et al. COPD immunopathology. Semin Immunopathol 2016; 38(4): 497–515.
• Bathoorn E, Liesker, Postma D et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis 2009; 101.
• Papi A, Luppi F, Franco F et al. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3(3): 245–51.
• Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci 2017; 131(13): 1.541–1.558.
• Mahler DA, Huang S, Tabrizi M et al. Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD. Chest 2004; 126(3): 926–934.
• Liang S, Dai J, Hou S et al. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab. J Biol Chem 2013; 288(19): 13.799–807.
• Vaart H Van Der, Koëter GH, Postma DS et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172(4): 465–469.
• Rennard SI, Flavin SK, Agarwal PK et al. Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Respir Med 2013; 107(3): 424–432.
• Suissa S, Ernst P, Hudson M. TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21(1): 234–238.
• Barnes PJ. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(9): 866–7.
• Calverley PMA, Sethi S, Dawson M et al. A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res 2017; 18(1)
• National Health Institute. Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients. ClinicalTrials.gov Identifier NCT00581945.
• Singh DMU. Biologics for Chronic Obstructive Pulmonary Disease: Present and Future. Barcelona Respir Netw Rev 2018; (4): 34–52.
• Pavord ID. Biologics and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141(6): 1.983–1.991.
• Stefano A Di, Caramori G, Gnemmi I et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 2009;
• Doe C, Bafadhel M, Siddiqui S et al. Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD. Chest 2010; 138(5): 1.140–1.147.
• Busse WW, Holgate S, Kerwin E et al. Randomized, double-blind, placebocontrolled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188(11): 1.294–302.
• Miravitlles M, Soler-Cataluña JJ, Calle M et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol 2017; 53(6): 324–335.
• Bafadhel M, McKenna S, Terry S et al. Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2012; 186(1): 48–55.
• Benson VS, Pascoe KC, Siddall J et al. Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy. Int J Chron Obstruct Pulmon Dis 2019;Volume 14: 2.711–2.723.
• Mkorombindo T, Dransfield MT. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2019;Volume 14: 1.779–1.787.
• Ortega HG, Yancey SW, Mayer B et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4(7): 549–556.
• Yancey S, Albers FC, Gunsoy N et al. Effect of mepolizumab on exacerbations in asthma patients with features common in COPD. AmJ Resp Crit Care Med 2017; 195: A4683.
• Pavord ID, Chanez P, Criner GJ et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med 2017; 377(17): 1.613–1.629.
• Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis 2019; 14: 1.045–1.051.
• Shahlavi‑Monavvar P, Mobasher-Jannat A. Mepolizumab for Eosinophilic COPD. N Engl J Med 2018; 378(7): 681.
• Bafadhel M, McKenna S, Terry S et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184(6): 662–71.
• Negewo NA, McDonald VM, Baines KJ et al. Peripheral blood eosinophils: A surrogate marker for airway eosinophilia in stable COPD. Int J COPD 2016; 11(1): 1.495–1.504.
• Zysman M, Deslee G, Caillaud D et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 1.819–1.824.
• Keene JD, Jacobson S, Kechris K et al. Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. Am J Respir Crit Care Med 2017; 195(4): 473–481.
• Ortega HG, Liu MC, Pavord ID et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med 2014; 371(13): 1.198–1.207.
• Dasgupta A, Kjarsgaard M, Capaldi D et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J 2017; 49(3)
• Fernandez Romero GA, Beros J, Criner G. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations. Expert Rev Respir Med 2019; 13(2): 125–132.
• Condreay L, Chiano M, Ortega H et al. No genetic association detected with mepolizumab efficacy in severe asthma. Respir Med 2017; 132: 178–180.
• Condreay LD, Gao C, Bradford E et al. No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia. Respir Med 2019;
• Kolbeck R, Kozhich A, Koike M et al. MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;
• FitzGerald JM, Bleecker ER, Nair P et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2016;
• Bleecker ER, FitzGerald JM, Chanez P et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388(10056): 2.115–2.127.
• Zeiger RS, Tran TN, Butler RK et al.Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease. J allergy Clin Immunol Pract 2018; 6(3): 944-954.e5.
• Alcázar-Navarrete B, Rodríguez OR, Baena PC et al. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J 2018;
• Pascoe S, Barnes N, Brusselle G et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019; 0(0)
• Brightling CE, Bleecker ER, Panettieri RA et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebocontrolled, phase 2a study. Lancet Respir Med 2014; 2(11): 891–901.
• Criner GJ, Celli BR, Brightling CE et al. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med 2019; 381(11): 1.023–1.034.
• A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebocontrolled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) ClinicalTrials. gov Identifier: NCT04053634. - Available at www.ClinicalTrials.gov
• Rogliani P, Matera MG, Puxeddu E et al. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulm Pharmacol Ther 2018; 50: 28–37.
• National Health Institute. Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderateto-severe COPD With Type 2 Inflammation. ClinicalTrials.gov Identifier NCT03930732.
• Hanania NA, Noonan M, Corren J et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebocontrolled studies. Thorax 2015; 70(8): 748– 756.
• National Health Institute. A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) ClinicalTrials. gov Identifier:NCT02546700.
• Brightling CE, Chanez P, Leigh R et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebocontrolled, phase 2b trial. Lancet Respir Med 2015;
• Gauvreau GM, O’Byrne PM, Boulet L-P et al. Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. N Engl J Med 2014; 370(22): 2.102–2.110.
• National Health Institute. Tezepelumab COPD Exacerbation Study (COURSE) ClinicalTrials.gov Identifier:NCT04039113.
• Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;
• Global Initiative for Asthma/Global Initiative for Chronic Obstructive Lung Disease. Diagnosis and initial treatment of: Asthma, COPD and Asthma-COPD Overlap, 2017.
• Plaza V, Álvarez F, Calle M et al. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA) Arch Bronconeumol 2017; 53(8): 443– 449.
• Tat TS, Cilli A. Omalizumab treatment in asthma-COPD overlap syndrome. J Asthma 2016;
• Yalcin AD, Celik B, Yalcin AN. Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol Immunotoxicol 2016.
• Maltby S, Gibson PG, Powell H, McDonald VM. Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD. Chest 2017.
• Normansell R, Walker S, Milan SJ et al. Omalizumab for asthma in adults and children. Cochrane Database Syst. Rev. 2014.
• Casale TB, Luskin AT, Busse W et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective RealWorld Study. J Allergy Clin Immunol Pract 2019.
• Hanania NA, Chipps BE, Griffin NM et al. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol 2019.